logo
welcome
Reuters

Reuters

US FDA lifts partial clinical hold on Rezolute's low blood sugar treatment

Reuters
Summary
Nutrition label

81% Informative

FDA lifts partial clinical hold on late-stage study testing company's treatment for low blood sugar.

Hold was placed last year due to historical data that reflected liver toxicity in lab rats following the company's therapy, ersodetug.

FDA concluded liver toxicity observed was likely specific to a particular type of rats called Sprague Dawley , not otherwise relevant to humans.

VR Score

92

Informative language

97

Neutral language

83

Article tone

formal

Language

English

Language complexity

65

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links